Mutations in a gene called KRAS are causally associated with acquired resistance to targeted therapies for colorectal cancers (CRC), according to new findings from EU-funded researchers from Italy and their research colleagues in the United States. Writing in the journal Nature, the team explain that patients often develop resistance to colorectal cancer drugs that target epidermal growth factor receptors (EGFRs).